138 related articles for article (PubMed ID: 23558559)
1. Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer.
Suzuki Y; Ogiya R; Oshitanai R; Terao M; Terada M; Morioka T; Tsuda B; Niikura N; Okamura T; Saito Y; Tokuda Y
Int J Clin Oncol; 2014 Apr; 19(2):274-9. PubMed ID: 23558559
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
Takashima T; Nakayama T; Yoshidome K; Kawajiri H; Kamigaki S; Tsurutani J; Arai T; Ito T; Komoike Y; Doi T; Masuda N; Miyauchi K; Miyoshi Y; Sakamoto J; Morita S; Taguchi T
Anticancer Res; 2014 Jul; 34(7):3583-8. PubMed ID: 24982373
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.
Kojima Y; Yoshie R; Kawamoto H; Shimo A; Uejima T; Iwatani T; Motoyoshi A; Kanemaki Y; Boku N; Tsugawa K
Oncology; 2019; 96(6):309-317. PubMed ID: 30893699
[TBL] [Abstract][Full Text] [Related]
4. Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).
Fujii T; Horiguchi J; Yanagita Y; Koibuchi Y; Ikeda F; Uchida N; Kimura M;
Anticancer Res; 2018 Feb; 38(2):905-909. PubMed ID: 29374719
[TBL] [Abstract][Full Text] [Related]
5. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
6. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
7. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Cardoso F; Canon JL; Amadori D; Aldrighetti D; Machiels JP; Bouko Y; Verkh L; Usari T; Kern KA; Giorgetti C; Dirix L
Breast; 2012 Dec; 21(6):716-23. PubMed ID: 23022045
[TBL] [Abstract][Full Text] [Related]
8. Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab.
Saito Y; Oshitanai R; Terao M; Terada M; Tsuda B; Okamura T; Suzuki Y; Tokuda Y
Jpn J Clin Oncol; 2011 Sep; 41(9):1051-8. PubMed ID: 21810868
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.
Tsurutani J; Kuroi K; Iwasa T; Miyazaki M; Nishina S; Makimura C; Tanizaki J; Okamoto K; Yamashita T; Aruga T; Shigekawa T; Komoike Y; Saeki T; Nakagawa K
Cancer Sci; 2015 Jun; 106(6):734-739. PubMed ID: 25786335
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).
Kurokawa Y; Sugimoto N; Miwa H; Tsuda M; Nishina S; Okuda H; Imamura H; Gamoh M; Sakai D; Shimokawa T; Komatsu Y; Doki Y; Tsujinaka T; Furukawa H
Br J Cancer; 2014 Mar; 110(5):1163-8. PubMed ID: 24473399
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
MartÃn M; Makhson A; Gligorov J; Lichinitser M; Lluch A; Semiglazov V; Scotto N; Mitchell L; Tjulandin S
Oncologist; 2012; 17(4):469-75. PubMed ID: 22467666
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
[TBL] [Abstract][Full Text] [Related]
14. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
[TBL] [Abstract][Full Text] [Related]
15. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
16. Combination trastuzumab and chemotherapy may have a role in women with small, node-negative, human epidermal growth factor receptor 2-positive breast cancer.
McArthur HL; Morris PG; Hudis CA
J Clin Oncol; 2015 Jan; 33(1):124-5. PubMed ID: 25403210
[No Abstract] [Full Text] [Related]
17. Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
Nakayama T; Morita S; Takashima T; Kamigaki S; Yoshidome K; Ito T; Taguchi T; Sakamoto J; Noguchi S
Anticancer Res; 2011 Sep; 31(9):3035-9. PubMed ID: 21868555
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).
Ishiguro H; Saji S; Nomura S; Tanaka S; Ueno T; Onoue M; Iwata H; Yamanaka T; Sasaki Y; Toi M
Cancer Med; 2017 Dec; 6(12):2909-2917. PubMed ID: 29131533
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
20. How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers.
Reeder-Hayes KE; Carey LA
J Clin Oncol; 2014 Jul; 32(20):2122-4. PubMed ID: 24888811
[No Abstract] [Full Text] [Related]
[Next] [New Search]
